Co-Authors
This is a "connection" page, showing publications co-authored by Carlo Perno and Andrea Antinori.
Connection Strength
0.634
-
Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients. New Microbiol. 2019 Apr; 42(2):69-80.
Score: 0.202
-
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice. Virus Genes. 2019 Jun; 55(3):290-297.
Score: 0.051
-
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. J Antimicrob Chemother. 2018 12 01; 73(12):3460-3470.
Score: 0.050
-
New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). Chem Biol Drug Des. 2019 01; 93(1):50-59.
Score: 0.050
-
Genetic divergence of HIV-1 B subtype in Italy over the years 2003-2016 and impact on CTL escape prevalence. Sci Rep. 2018 10 24; 8(1):15739.
Score: 0.049
-
Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. J Clin Virol. 2018 07; 104:61-64.
Score: 0.048
-
Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessment. New Microbiol. 2018 Apr; 41(2):112-117.
Score: 0.048
-
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice. Antivir Ther. 2018; 23(3):249-257.
Score: 0.047
-
Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains. J Clin Microbiol. 2017 09; 55(9):2827-2837.
Score: 0.045
-
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol. 2017 06; 2(6):427-434.
Score: 0.044